Concert Pharmaceuticals Highlights CTP-656 Phase 1 Results at North American Cystic Fibrosis Conference

Concert Pharmaceuticals, Inc.

today presented results from a Phase 1 single ascending dose trial of CTP-656, a next generation potentiator being developed for the treatment of cystic fibrosis. In the Phase 1 healthy volunteer trial comparing CTP-656 to current standard of care Kalydeco®, CTP-656 provided a superior pharmacokinetic profile that supports once-daily dosing. CTP-656 is a new chemical entity designed by Concert to provide superior pharmacokinetic properties while leveraging the known safety and efficacy of Kalydeco. The results were presented during a poster session at the North American Cystic Fibrosis Conference in Phoenix, AZ. "With CTP-656 we aim to develop another treatment option to meaningfully enhance patient care. In this Phase 1 trial,